Does oral anticoagulation with edoxaban or apixaban reduce the risk of stroke in patients with device-detected atrial fibrillation?
Patients with device-detected atrial fibrillation (meta-analysis of 2 large randomized trials: NOAH-AFNET 6 and ARTESiA)
Oral anticoagulation with direct oral anticoagulants (edoxaban or apixaban)
Strokehard clinical
In patients with device-detected atrial fibrillation, oral anticoagulation with edoxaban or apixaban effectively reduces stroke risk at the cost of increased major bleeding.
The results of the NOAH-AFNET 6 and ARTESiA trials are consistent with each other. Meta-analysis of these 2 large randomized trials provides high-quality evidence that oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected atrial fibrillation and increases the risk of major bleeding.
Building similarity graph...
Analyzing shared references across papers
Loading...
William F. McIntyre
Alexander P. Benz
Nina Becher
Circulation
Imperial College London
Duke University
McMaster University
Building similarity graph...
Analyzing shared references across papers
Loading...
McIntyre et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69d570ea75589c71d767e01d — DOI: https://doi.org/10.1161/circulationaha.123.067512